Jasper Therapeutics, Inc.

NasdaqCM:JSPR Stock Report

Market Cap: US$36.7m

Jasper Therapeutics Future Growth

Future criteria checks 0/6

Jasper Therapeutics's earnings are forecast to decline at 14.7% per annum while its annual revenue is expected to grow at 54.9% per year. EPS is expected to grow by 38.7% per annum.

Key information

-14.7%

Earnings growth rate

38.73%

EPS growth rate

Biotechs earnings growth21.9%
Revenue growth rate54.9%
Future return on equityn/a
Analyst coverage

Good

Last updated10 Feb 2026

Recent future growth updates

Recent updates

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky

Jan 08
Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky

Here's Why Jasper Therapeutics (NASDAQ:JSPR) Must Use Its Cash Wisely

May 30
Here's Why Jasper Therapeutics (NASDAQ:JSPR) Must Use Its Cash Wisely

Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Deliver On Growth Plans?

Jan 04
Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Deliver On Growth Plans?

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma

Nov 18

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Aug 30
We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Jan 23
We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

Jul 31
Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Feb 02
We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely

Oct 14
Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely

Jasper Therapeutics GAAP EPS of -$0.29 beats by $0.02

Aug 12

Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Invest In Growth?

Jun 19
Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Invest In Growth?

Earnings and Revenue Growth Forecasts

NasdaqCM:JSPR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028N/A-133-100-1023
12/31/2027N/A-111-104-944
12/31/2026N/A-89-87-866
12/31/2025N/A-84-72-716
9/30/2025N/A-91-77-76N/A
6/30/2025N/A-91-74-73N/A
3/31/2025N/A-79-70-70N/A
12/31/2024N/A-71-63-63N/A
9/30/2024N/A-64-59-58N/A
6/30/2024N/A-62-56-56N/A
3/31/2024N/A-64-58-57N/A
12/31/2023N/A-64-52-52N/A
9/30/2023N/A-61-48-48N/A
6/30/2023N/A-55-46-46N/A
3/31/2023N/A-50-43-42N/A
12/31/2022N/A-38-46-46N/A
9/30/2022N/A-34-49-48N/A
6/30/2022N/A-25-47-45N/A
3/31/2022N/A-23-43-42N/A
12/31/2021N/A-31-36-34N/A
9/30/2021N/A-32-26-24N/A
6/30/2021N/A-39-27-25N/A
3/31/2021N/A-40-24-23N/A
12/31/2020N/A-32-18-18N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: JSPR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: JSPR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: JSPR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: JSPR is forecast to have no revenue next year.

High Growth Revenue: JSPR is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if JSPR's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/11 16:09
End of Day Share Price 2026/02/11 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Jasper Therapeutics, Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Justin ZelinBTIG
Timothy ChiangCapital One Securities, Inc.
Silvan TuerkcanCitizens JMP Securities, LLC